Cargando…
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vac...
Autores principales: | Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420701/ https://www.ncbi.nlm.nih.gov/pubmed/36127228 http://dx.doi.org/10.1016/j.dld.2022.08.027 |
Ejemplares similares
-
COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021) -
PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY
por: Macaluso, F.S., et al.
Publicado: (2022) -
OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
por: Todeschini, A., et al.
Publicado: (2022) -
Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
por: Arrigo, Serena, et al.
Publicado: (2021) -
OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY
por: Macaluso, F.S., et al.
Publicado: (2023)